Navigation Links
Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
Date:4/6/2011

llion ($15 million per year) over the two years beginning with the first commercial sale of DIFICID. Cubist is also eligible to receive an additional $5 million in the first year after first commercial sale and $12.5 million in the second year of the agreement if mutually agreed upon annual sales targets are achieved, as well as a portion of Optimer's gross profits from any sales above the specified annual sales target levels.

Scheduled Conference Call

Optimer will host a conference call today at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss the outcome of the Anti-Infective Drugs Advisory Committee as well as the Cubist collaboration. To participate in the conference call, please dial (877) 280-7280 from the U.S., or (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Conference Call." The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call. Please connect to Optimer's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. 

About DIFICID™ (Fidaxomicin)

DIFICID™ (fidaxomicin) is an investigational antibiotic with a novel mechanism of action, which inhibits the bacterial enzyme RNA polymerase, resulting in the rapid killing of C. difficile. The narrow-spectrum profile of DIFICID eradicates C. difficile selectively with minimal disruption to the normal intestinal flora, while the alternative antibiotics used to treat CDI, metronidazole and vancomycin, have been shown to disrupt the gut flora. DIFICID facilitates the return of normal physiological conditions in the colon which may be responsible for reducing CDI recurrence rates. In two Phase 3 trials for the treatment of CD
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
2. Trading Halted Today in Optimer Pharmaceuticals Stock
3. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
4. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
5. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
6. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
7. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
8. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
9. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
10. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- According to a new market research report ... Ethylene Oxide, Filtration, E-beam, Gamma), Services (Onsite & Offsite), Consumables ... Forecast to 2020", published by MarketsandMarkets, The Sterilization Equipment Market ... at a CAGR of 7.6%.from 2015 to 2020. ... ables and 37 F ...
(Date:7/31/2015)... and SAN DIEGO , July 31, ... company Eisai Co., Ltd. (Headquarters: Tokyo ... and Halozyme Therapeutics, Inc. (Headquarters: San Diego, ... Torley , "NASDAQ: HALO") have signed a clinical collaboration ... ® , "eribulin") in combination with Halozyme,s investigational drug ...
(Date:7/30/2015)... 2015 Mettler-Toledo International Inc. (NYSE: MTD ... below are the highlights: , Sales in ... the prior year. Reported sales decreased 4% as currency ... , Net earnings per diluted share as reported (EPS) ... Adjusted EPS was $2.80 , an increase of ...
Breaking Medicine Technology:Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14
(Date:8/3/2015)... ... August 03, 2015 , ... Constantin Vasilica, 48 from Romania wanted ... caused by diabetes after many years of suffering and using medications with strong side ... want to ask for extra time off or wait longer hours in the waiting ...
(Date:8/3/2015)... , ... August 03, 2015 ... ... a leading provider of medical information, risk management and investigative services, has ... and direction toward focused, expert information solutions that improve business outcomes for ...
(Date:8/3/2015)... ... August 03, 2015 , ... Recent reports by the American ... at least once in their lives. Often time, low back and sciatic pain can ... could only be managed clinically with powerful pain medication or spinal surgery. Dynamic ...
(Date:8/2/2015)... (PRWEB) , ... August 03, 2015 , ... For many “would be” entrepreneurs, starting ... get help” or “I can’t afford to start a business.” Neither needs be a major ... right and theoretical opportunity to start a business and be successful. The risks of starting ...
(Date:8/1/2015)... ... August 02, 2015 , ... AlignLife Office Coordinator Heather ... continuity of care for patients at this natural health care center in Winamac. , ... Mary Heal said. "Heather's role is vital to our approach because we want to ...
Breaking Medicine News(10 mins):Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Dynamic Health Care in Louisville, KY, Offers a New and Cutting-Edge Therapy for Low Back & Leg Pain Sufferers 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:New Patient Advocate Enhances Natural Health Care 2
... help diagnose disease early, study shows, , TUESDAY, July ... fluid may accurately identify the people with mild cognitive ... a new study finds. , Changes in the chemistry ... of Alzheimer,s disease. If and when treatments are available ...
... ... programs included in prestigious national rankings , ... Indianapolis, IN (Vocus) July 21, 2009 -- Nine clinical programs ... the top 50 national programs in U.S. News & World Report,s "2009-10 America,s Best ...
... found on how they help arteries stay clear and healthy ... genetic technology, researchers have begun to discover the exact molecular ... spice -- and ordinary orange juice are good for the ... are reporting studies describing the range of genes that are ...
... - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com ... MEVAC-A for the country of Thailand. The registration is ... 2009. , This registration is required to accommodate a ... Mellow Hope products such as MEVAC-A, MEVAC-DTaP, and MEVAC-ACYW. ...
... (July 21, 2009) Columbia University Medical Center,s Jeffrey ... of schizophrenia, has been selected by the National Institute ... Health as principal investigator of a nationwide effort to ... experiencing a first episode of the psychotic symptoms of ...
... , MINNEAPOLIS, July 21 Providing a ... more productive workforce. However, without employee engagement, even the best wellness ... (NYSE Amex: FIT ) explores how Herbalife is motivating ... Life program. , , (Logo: ...
Cached Medicine News:Health News:Biomarkers May Predict Alzheimer's 2Health News:Biomarkers May Predict Alzheimer's 3Health News:Clarian Health/Indiana University School of Medicine Specialty Programs Ranked Among Best in Nation 2Health News:Clarian Health/Indiana University School of Medicine Specialty Programs Ranked Among Best in Nation 3Health News:Studies Show Genetic Activity of Antioxidants 2Health News:Studies Show Genetic Activity of Antioxidants 3Health News:Hard To Treat Diseases (HTDS.PK) Thailand Registration 2Health News:Columbia leads national effort to develop early intervention for schizophrenia 2Health News:Columbia leads national effort to develop early intervention for schizophrenia 3Health News:HealthFitness Helps Herbalife Engage Employees in Wellness Promotion Program Through Strategic Use of Incentives 2Health News:HealthFitness Helps Herbalife Engage Employees in Wellness Promotion Program Through Strategic Use of Incentives 3
The ENDO CLOSE™ trocar site closure device has application in laparoscopic procedures for approximation of tissues and percutaneous suturing for closing incision sites....
... of a 42" long suture inserted into a ... one end and scored on the other. The ... to a ST-3 needle. The opposite end of ... of the plastic tube. The scored end acts ...
... long ligature inserted into a plastic tube. The plastic ... the other. The suture protrudes from the narrow end ... knot which becomes secure after the device is activated. ... the scored end of the plastic tube. The scored ...
... consists of 18'' long ligature inserted into a plastic ... and scored on the other. The suture protrudes from ... loop with a knot which becomes secure after the ... is fastened to the scored end of the plastic ...
Medicine Products: